Patent•
Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
28 Feb 2005-
TL;DR: A method for the treatment and/or prophylaxis of an ostenonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia, Legg-Calve-Perthes disease and femoral head necrosis was proposed in this paper.
Abstract: A method for the treatment and/or prophylaxis of an ostenonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
Citations
More filters
Patent•
06 May 2004
TL;DR: Water-soluble strontium salts have a water-solubility of from about 1 g/l to about 100 g/L at room temperature as mentioned in this paper. But they are not suitable for use in the treatment and/or prophylaxis of cartilage and bone conditions and for methods of treating such condition.
Abstract: Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.
29 citations
Patent•
21 Aug 2014
TL;DR: In this article, a method of making composite fibers by surface treatment of fibers followed by either treating such fibers with premade crystallization seeds or by precipitation and direct crystallization of seeds onto pretreated fibers is described.
Abstract: Fibers with crystallization seeds attached to its surface, method of making such composite fibers by surface treatment of fibers followed by either treating such fibers with premade crystallization seeds or by precipitation and direct crystallization of seeds onto pretreated fibers. Controlling and tuning the properties of inorganic binder compositions with fiber- bound crystallization seeds and thereby generating inorganic binder compositions with tailor-made characteristics.
12 citations
Patent•
05 May 2005
TL;DR: In this paper, a new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids, was presented.
Abstract: A new method for preparing salts of metal cations and organic acids, especially divalent salts of alkaline earth metal ions from group II of the periodic system and carboxylic acids. The method comprising the use of a high temperature (about 90° or more) and, optionally. high pressure, in order to obtain a higher yield, purity and faster reaction speed than obtained with known synthesis methods. In particular, the present invention relates to the production of strontium salts of carboxylic acids. Novel strontium salts are also provided by the present method.
12 citations
Patent•
18 Apr 2008TL;DR: In this paper, a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound.
Abstract: A composition for use in bone healing and bone regeneration in the form of a viscoelastic hydrogel gel or liquid formulation comprising fibrinogen, thrombin and an inorganic component comprising a strontium (Sr) containing compound and/or possibly another metal such as a calcium containing compound. The strontium containing compound can be dissolved in the thrombin solutions or added to the clot in crystalline particulate form. Upon mixing the components, gelation takes place to form a matrix. The composition may also comprise an iodine-containing compound which acts as a plasticizer.
11 citations
Patent•
07 Nov 2005
TL;DR: The tablets are designed to contain a very high load of the strontium salt (75% w/w or more), which is especially advantageous due to the fact that straconium must be administered in relative high amounts for therapeutic use as mentioned in this paper.
Abstract: Tablets comprising strontium in the form of a strontium salt such as strontium malonate The tablets are designed to contain a very high load of the strontium salt (75% w/w or more), which is especially advantageous due to the fact that strontium must be administered in relative high amounts for therapeutic use Furthermore, the tablets provided by the present invention lead to an improved bioavailability and presents a therapeutic advantage
10 citations
References
More filters
Book•
01 Aug 1982
TL;DR: The world's most widely used medical reference now features expanded clinical focus on each category of disorder, as well as more specific guidance on patient examinations, in the thoroughly revised and updated 18th Edition.
Abstract: The world's most widely used medical reference now features expanded clinical focus on each category of disorder, as well as more specific guidance on patient examinations The thoroughly revised and updated 18th Edition is packed with essential information on diagnosing and treating medical disorders to help medical professionals deliver the best care to their patients This handy, compact guide was written by a team of clinicians for everyday use Designed for maximum clinical utility, the new Merck Manual of Diagnosis and Therapy makes it easy to find the right information, right when it is needed It is a must-have for medical students, residents, practicing physicians, nurses, and allied health professionals Featuring: * All new "approach" chapters * All-new abstract summaries *341 total chapters *34 completely new chapters *69 new illustrations * New cross-referencing * Two-color presentation * Brand new content on: critical care medicine, metabolic syndrome, acute lung injury, biological warfare and terrorism, SARS, smallpox, and more
1,908 citations
TL;DR: Evidence is provided that glucocorticoid-induced bone disease arises from changes in the numbers of bone cells, whereas decreased production and apoptosis of osteoblasts would account for the decline in bone formation and trabecular width.
Abstract: Glucocorticoid-induced bone disease is characterized by decreased bone formation and in situ death of isolated segments of bone (osteonecrosis) suggesting that glucocorticoid excess, the third most common cause of osteoporosis, may affect the birth or death rate of bone cells, thus reducing their numbers. To test this hypothesis, we administered prednisolone to 7-mo-old mice for 27 d and found decreased bone density, serum osteocalcin, and cancellous bone area along with trabecular narrowing. These changes were accompanied by diminished bone formation and turnover, as determined by histomorphometric analysis of tetracycline-labeled vertebrae, and impaired osteoblastogenesis and osteoclastogenesis, as determined by ex vivo bone marrow cell cultures. In addition, the mice exhibited a threefold increase in osteoblast apoptosis in vertebrae and showed apoptosis in 28% of the osteocytes in metaphyseal cortical bone. As in mice, an increase in osteoblast and osteocyte apoptosis was documented in patients with glucocorticoid-induced osteoporosis. Decreased production of osteoclasts explains the reduction in bone turnover, whereas decreased production and apoptosis of osteoblasts would account for the decline in bone formation and trabecular width. Furthermore, accumulation of apoptotic osteocytes may contribute to osteonecrosis. These findings provide evidence that glucocorticoid-induced bone disease arises from changes in the numbers of bone cells.
1,621 citations
TL;DR: Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures.
Abstract: background Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug that dissociates bone remodeling by increasing bone formation and decreasing bone resorption, has been shown to reduce the risk of vertebral fractures and to increase bone mineral density. methods To evaluate the efficacy of strontium ranelate in preventing vertebral fractures in a phase 3 trial, we randomly assigned 1649 postmenopausal women with osteoporosis (low bone mineral density) and at least one vertebral fracture to receive 2 g of oral strontium ranelate per day or placebo for three years. We gave calcium and vitamin D supplements to both groups before and during the study. Vertebral radiographs were obtained annually, and measurements of bone mineral density were performed every six months. results New vertebral fractures occurred in fewer patients in the strontium ranelate group than in the placebo group, with a risk reduction of 49 percent in the first year of treatment and 41 percent during the three-year study period (relative risk, 0.59; 95 percent confidence interval, 0.48 to 0.73). Strontium ranelate increased bone mineral density at month 36 by 14.4 percent at the lumbar spine and 8.3 percent at the femoral neck (P<0.001 for both comparisons). There were no significant differences between the groups in the incidence of serious adverse events. conclusions Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures.
1,582 citations
TL;DR: In addition to its antiresorptive activity, strontium was found to have anabolic activity in bone, and this may have significant beneficial effects on bone balance in normal and osteopenic animals.
Abstract: The processes of bone resorption and formation are tightly governed by a variety of systemic and local regulatory agents. In addition, minerals and trace elements affect bone formation and resorption through direct or indirect effects on bone cells or bone mineral. Some trace elements closely chemically related to calcium, such as strontium (Sr), have pharmacological effects on bone when present at levels higher than those required for normal cell physiology. Indeed, strontium was found to exert several effects on bone cells. In addition to its antiresorptive activity, strontium was found to have anabolic activity in bone, and this may have significant beneficial effects on bone balance in normal and osteopenic animals. Accordingly, strontium has been thought to have potential interest in the treatment of osteoporosis. This review summarizes the mechanisms of action of strontium on bone cells, the evidence for its beneficial effects on bone mass in vivo, and its potential therapeutic effects in osteopenic disorders.
618 citations
TL;DR: Infiltration of strontium into bone, mainly by exchange onto the crystal surface, is dependent on the duration of treatment, dose, gender, and skeletal site, and, in bone, between the different skeletal sites.
534 citations